Company profile: Vedanta Biosciences
1.1 - Company Overview
Company description
- Provider of microbiome-derived therapies that modulate the gut microbiota to address immune and infectious diseases via orally administered defined bacterial consortia. Pipeline includes VE303 for preventing Clostridioides difficile infection recurrence (Phase 2 met primary efficacy endpoint), VE202 for IBD, and VE707 for MDROs (including CRE, ESBL, VRE); backed by CARB-X research grants.
Products and services
- VE303: An orally administered, defined bacterial consortium of 8 clonal human commensal strains engineered to prevent recurrent Clostridioides difficile infection, with Phase 2 efficacy met in the CONSORTIUM trial
- VE707: A preclinical, orally administered bacterial consortium architected to prevent infection and colonization recurrence by multidrug-resistant organisms, including CRE, ESBL, and VRE, targeting gut microbiota
- VE202: A rationally-designed bacterial consortium candidate consisting of clonal human commensal strains created for potential inflammatory bowel disease treatment by modulating gut microbiota
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Vedanta Biosciences
Seres Therapeutics
HQ: United States
Website
- Description: Provider of microbiome therapeutics, including VOWST, an FDA-approved oral microbiota-based therapy to prevent recurrent Clostridioides difficile infection in adults after antibacterial treatment; SER-155, an investigational oral microbiome therapeutic aimed at reducing gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients; and a platform to design, test, and manufacture bacterial consortia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Seres Therapeutics company profile →
Infinant Health
HQ: United States
Website
- Description: Provider of infant gut microbiome solutions, offering Evivo Powder, a daily supplement for infants fed any amount of breast milk to establish a protective gut microbiome and support healthy immune function, and B. infantis EVC001, a bacterial strain discovered by Infinant Health and proven pivotal to infant immune health, particularly when combined with breast milk.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Infinant Health company profile →
Xycrobe
HQ: United States
Website
- Description: Provider of early-stage biotechnology research and development leveraging extensive human microbiome data to develop novel therapies for clinical applications, with innovations that utilize microbes as delivery vehicles.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Xycrobe company profile →
Adaptive Phage Therapeutics
HQ: United States
Website
- Description: Provider of phage-based therapeutic services for multi-drug resistant pathogenic bacteria, using clinical technology to match phages to patient-specific infections; offerings include BX004 for cystic fibrosis Pseudomonas aeruginosa, BX211 for diabetic foot osteomyelitis, personalized and optimized phage therapies, and the XMarker platform for microbial biomarker discovery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Adaptive Phage Therapeutics company profile →
4D Pharma
HQ: United Kingdom
Website
- Description: Provider of live biotherapeutics, a novel class of drugs defined by the FDA as biological products containing a live organism, such as bacteria, applicable to the prevention, treatment or cure of disease; developer of MicroRx, a proprietary platform.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full 4D Pharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Vedanta Biosciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Vedanta Biosciences
2.2 - Growth funds investing in similar companies to Vedanta Biosciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Vedanta Biosciences
4.2 - Public trading comparable groups for Vedanta Biosciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →